NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
28.46 -0.40 (-1.39%)
At close: 29 October at 4:00 pm GMT-4
28.52 +0.06 (+0.21%)
Pre-market: 5:59 am GMT-4
Advanced chart
Loading Chart for PFE
DELL
  • Previous close 28.86
  • Open 29.01
  • Bid 28.45 x 2200
  • Ask --
  • Day's range 28.02 - 29.17
  • 52-week range 25.20 - 31.54
  • Volume 76,804,259
  • Avg. Volume 30,547,654
  • Market cap (intra-day) 161.274B
  • Beta (5Y monthly) 0.62
  • PE ratio (TTM) 37.95
  • EPS (TTM) 0.75
  • Earnings date 28 Jan 2025 - 3 Feb 2025
  • Forward dividend & yield 1.68 (5.82%)
  • Ex-dividend date 8 Nov 2024
  • 1y target est 33.11

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Drug Manufacturers - General

Industry

More about Pfizer Inc.

Recent news: PFE

View more
View more

Related videos: PFE

Pfizer CEO on company's 'exceptional quarter' & Starboard fight

After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market Domination to discuss the "exceptional quarter." Bourla notes that Pfizer in addition to earnings and revenue, the company's COVID and non-COVID businesses also topped expectations. He tells Yahoo Finance, "When you have a quarter like that, really you feel that you are in a good way of executing what you said you will do." While there have been questions about the sustainability of Pfizer's COVID business, Bourla explains, "It's clear to me that the COVID business has stabilized into the new levels that will be the sustainable levels for the future. We are having already a second year of repetition." As Pfizer continues its proxy battle with activist investor Starboard Value, Bourla says that he agrees with some of the points made, like poor shareholder returns. However, he disagrees with "a lot" of other points, like spending and acquisitions, and calls the Pfizer-BioNTech (BNTX) deal "transformational." He notes that Starboard Value CEO Jeff Smith has said that there are many changes that need to be made in the company. However, he believes that he has already addressed the main issues: "I changed everything 12 months ago. Let me repeat what we did as changes. We changed our commercial model with new leaders and US international separated. We have delivered three consecutive quarters of growth... We announced a $4 billion cut in SI&A (selling, informational, and administrative) and OpEx (operational expenditures)." Bourla also points to leadership changes and new board members as initiatives to create new shareholder value. He argues that these efforts have been working and has led the company to perform "very well." To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Melanie Riehl
Yahoo Finance Video · 11 hr ago
PFE
-1.39%

Performance overview: PFE

Trailing total returns as of 29/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD return

PFE
3.29%
S&P 500
22.29%

1-year return

PFE
0.10%
S&P 500
41.67%

3-year return

PFE
25.02%
S&P 500
26.90%

5-year return

PFE
0.90%
S&P 500
91.91%

Compare to: PFE

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

PFE
Pfizer Inc.
28.46
-1.39%
Mkt cap 161.274B
Industry Drug Manufacturers—General
MRK
Merck & Co., Inc.
103.73
-0.48%
Mkt cap 262.936B
Industry Drug Manufacturers—General
JNJ
Johnson & Johnson
160.09
-0.93%
Mkt cap 385.436B
Industry Drug Manufacturers—General
BMY
Bristol-Myers Squibb Company
52.50
-0.27%
Mkt cap 106.439B
Industry Drug Manufacturers—General
LLY
Eli Lilly and Company
903.58
+0.89%
Mkt cap 813.607B
Industry Drug Manufacturers—General
ABBV
AbbVie Inc.
189.45
-0.12%
Mkt cap 334.633B
Industry Drug Manufacturers—General
GILD
Gilead Sciences, Inc.
88.08
-0.77%
Mkt cap 109.659B
Industry Drug Manufacturers—General
NVO
Novo Nordisk A/S
111.98
-0.34%
Mkt cap 496.08B
Industry Drug Manufacturers—General
GSK
GSK plc
38.17
+0.77%
Mkt cap 77.847B
Industry Drug Manufacturers—General
AMGN
Amgen Inc.
316.00
-0.37%
Mkt cap 169.796B
Industry Drug Manufacturers—General
SNY
Sanofi
53.83
-0.97%
Mkt cap 136.338B
Industry Drug Manufacturers—General

Statistics: PFE

View more

Valuation measures

As of 29/10/2024

  • Market cap

    161.27B

  • Enterprise value

    222.85B

  • Trailing P/E

    37.95

  • Forward P/E

    10.16

  • PEG ratio (5-yr expected)

    0.22

  • Price/sales (ttm)

    2.68

  • Price/book (mrq)

    1.84

  • Enterprise value/revenue

    3.71

  • Enterprise value/EBITDA

    18.36

Financial highlights

Profitability and income statement

  • Profit margin

    -4.70%

  • Return on assets (ttm)

    0.94%

  • Return on equity (ttm)

    -2.74%

  • Revenue (ttm)

    55.17B

  • Net income avi to common (ttm)

    -2.59B

  • Diluted EPS (ttm)

    0.75

Balance sheet and cash flow

  • Total cash (mrq)

    7.1B

  • Total debt/equity (mrq)

    79.41%

  • Levered free cash flow (ttm)

    3.44B

View more

Research analysis: PFE

View more

Earnings per share

Consensus EPS
 

Revenue vs. Earnings

Revenue 17.7B
Earnings 4.46B
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analysts' price targets

27.00
33.11 Average
28.46 Current
45.00 High
 
View more

People also watch

JNJ Johnson & Johnson
160.09
-0.93%
 
MRK Merck & Co., Inc.
103.73
-0.48%
 
XOM Exxon Mobil Corporation
117.28
-1.36%
 
INTC Intel Corporation
22.90
-0.09%
 
JPM JPMorgan Chase & Co.
222.90
-1.15%
 
VZ Verizon Communications Inc.
41.33
-0.70%
 
WMT Walmart Inc.
81.70
-1.27%
 
CSCO Cisco Systems, Inc.
55.68
+0.72%
 
BAC Bank of America Corporation
42.53
-0.21%
 
PG The Procter & Gamble Company
167.17
-1.26%
 
GE GE Aerospace
174.05
-0.75%
 
KO The Coca-Cola Company
65.56
-1.66%
 
BMY Bristol-Myers Squibb Company
52.50
-0.27%
 
T AT&T Inc.
22.18
+0.32%
 
C Citigroup Inc.
64.69
+0.83%
 
DIS The Walt Disney Company
96.13
-0.07%